Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 208 Publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM.
Targets
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NGCyRXBEgXSxdH;4bYMhSXO|YYm= MXO0PEBp NEjoRllFVVOR M4Hs[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2= MlS4NlE2PzJ3OEm=
BAF3 M3XMN2N6fG:2b4jpZ{BCe3OjeR?= MUG0PEBp M365RWROW09? MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? M3vZelIyPTd{NUi5
BAF3 MVfDfZRwfG:6aXOgRZN{[Xl? M2nLfFQ5KGh? MWjEUXNQ NHjqdIdEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtid3n0bEBKSzVyIH;mJFAvOjhizszN M1rLVFIyPTd{NUi5
Kelly Mo\kR5l1d3SxeHnjJGF{e2G7 NXv3PIdsTE2VTx?= NY\HW2JvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> M1LEV|IyPTd{NUi5
SH-SY5Y M1v2VWN6fG:2b4jpZ{BCe3OjeR?= M2PCeGROW09? MnPHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjV|IN88US=> NFvhRmYzOTV5MkW4PS=>
SMS-KCN MWrDfZRwfG:6aXOgRZN{[Xl? MnTNSG1UVw>? MljUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=> NHHlZVkzOTV5MkW4PS=>
BAF3 MnjqR5l1d3SxeHnjJGF{e2G7 M3PFdVQ5KGh? NGfBNZZFVVOR MorER5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP MUiyNVU4OjV6OR?=
3T3 NYfaWGpqTnWwY4Tpc44hSXO|YYm= MVGxJIg> NETTN5hFVVOR NIfHZZdKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NFHZbVAzOThzMkSxOC=>
3T3-E M2fwemZ2dmO2aX;uJGF{e2G7 MWCxJIg> MkjCSG1UVw>? NHzMRoVKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? M{n4Z|IyQDF{NEG0
A549 MWLLbY5ie2ViQYPzZZk> MnPWNUBp NG\tcGJFVVOR NWLReotEUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO MWWyNVgyOjRzNB?=
BAF3-BCL M3zwSWZ2dmO2aX;uJGF{e2G7 NYSyVnVUOSCq M2fuemROW09? MW\Jcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO M17YbVIyQDF{NEG0
HEK293 MUTGeY5kfGmxbjDBd5NigQ>? MUKxJIg> NXfaeVZ6TE2VTx?= MWfJcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO MlnrNlE5OTJ2MUS=
HEK293 MlO3SpVv[3Srb36gRZN{[Xl? MUexJIg> MlzlSG1UVw>? NF7CUGJKdmirYnn0bY9vKG:oIFnSJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1? M3H5b|IyQDF{NEG0
Jurkat MVTGeY5kfGmxbjDBd5NigQ>? M1nsRVEhcA>? M4j0cmROW09? NYfJPXYxUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= MWiyNVgyOjRzNB?=
KARPAS299 M{Oz[2tqdmG|ZTDBd5NigQ>? NH;j[WYyKGh? NVO5O|g2TE2VTx?= NWTPVHY2UW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NG\BNmIzOThzMkSxOC=>
PAE MnfWSpVv[3Srb36gRZN{[Xl? MV2xJIg> MULEUXNQ NXv4UYZ4UW6qaXLpeIlwdiCxZjDUVmtDKGG|c3Xzd4VlKGG|IHfyc5d1cCCoYXP0c5IucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlM6QSEQvF2= M1;VPVIyQDF{NEG0
BAF3 MWTGeY5kfGmxbjDBd5NigQ>? Mm\2Nk0{KGR? NGKwT|FFVVOR MkG1TY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> MVmyN|c1OjJ3Mh?=
KARPAS299 MXnDfZRwfG:6aXOgRZN{[Xl? NHHxS3gzNTNiZB?= NYrJU2xUTE2VTx?= M2PnXGlEPTB;MD6wOlQzKM7:TR?= NF\jeVQzOzd2MkK1Ni=>
EBC1 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULXeGR6PzJiaB?= MnLLSG1UVw>? M4jaOGlEPTB;MD6wNlMh|ryP MkjmNlM6QTN|Mki=
HCT116 NWLZdlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{izPFczKGh? NGewbWFFVVOR NFriNIFKSzVyPUG0MlgzKM7:TR?= NXL2PXRtOjN7OUOzNlg>
MCF7 NHXXNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK3NkBp NESxbGdFVVOR MXHJR|UxRTlwNUig{txO M1fFbFI{QTl|M{K4
MDA-MB-231 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PvSlczKGh? MnHxSG1UVw>? MlrSTWM2OD1zMD64JO69VQ>? NV74NJl3OjN7OUOzNlg>
MKN45 M3[wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO3NkBp NX;xboFPTE2VTx?= NHnVOVJKSzVyPUCuNFE{KM7:TR?= NWLre|huOjN7OUOzNlg>
NCI-H441 NEe1eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f0bFczKGh? NGPMVFFFVVOR NFf1SndKSzVyPUG3MlI2KM7:TR?= MYOyN|k6OzN{OB?=
NCI-H661 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfHc|M4OiCq MX7EUXNQ NGrzT3pKSzVyPUGxMlQ4KM7:TR?= NUjpe2RqOjN7OUOzNlg>
SK-MEL-28 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ufZRrPzJiaB?= M3jqdmROW09? NH:3O2RKSzVyPUGwMlk4KM7:TR?= MnLxNlM6QTN|Mki=
SKOV3 M{LFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp MWnEUXNQ NGLnVHFKSzVyPUGyMlg2KM7:TR?= NEXGOpEzOzl7M{OyPC=>
SNU5 NFHPc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Bb29jPzJiaB?= MmnKSG1UVw>? MUjJR|UxRTBwMEG2JO69VQ>? M{W3VVI{QTl|M{K4
NCI-H2228 NGTGUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnFXW85PzJiaB?= NHToNGNFVVOR MYXJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN Mn3sNlQ1OzJ7MEm=
NCI-H3122 M{LwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[3NkBp MmDXSG1UVw>? NEDUWYlKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO M4DmfFI1PDN{OUC5
NCI-H3122 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWO|IhcA>? MoPwSG1UVw>? NYn1OmRNUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO NEjDeVIzPDR|MkmwPS=>
NCI-H3122 M2DXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi3NkBp Mnu1SG1UVw>? MYrJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= MXqyOFQ{OjlyOR?=
NIH-3T3 MXrLbY5ie2ViQYPzZZk> NX7VOmNjOSCq MWHEUXNQ MkG3TY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NFPIT|AzPDR|MkmwPS=>
NIH-3T3 MXHLbY5ie2ViQYPzZZk> MlTmNUBp M3TSOWROW09? MoLoTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO NI\jZlIzPDR|MkmwPS=>
NIH-3T3 M1;wTWtqdmG|ZTDBd5NigQ>? MWSxJIg> MV;EUXNQ NV\RRpg3UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP NIXOdnozPDR|MkmwPS=>
NIH-3T3 M13xeWtqdmG|ZTDBd5NigQ>? MYWxJIg> NHvEUYZFVVOR NV7X[YpWUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD64OFMh|ryP NWTtTlBQOjR2M{K5NFk>
NIH-3T3 NHXYfGFMcW6jc3WgRZN{[Xl? MVuxJIg> NHzpPYRFVVOR MoqwTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO MXeyOFQ{OjlyOR?=
BAF3 NYXvXZZrTnWwY4Tpc44hSXO|YYm= MYi3NkBp NIXtXZFFVVOR MX;Jcohq[mm2aX;uJI9nKE6STT;BUGshfHKjboPm[YN1\WRiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNE4xPTFizszN MV[yOFQ3QDZ|Mh?=
BAF3 MXzDfZRwfG:6aXOgRZN{[Xl? MWW3NkBp MnfiSG1UVw>? MkXKTWM2OD1yLkm4JO69VQ>? M2\6TlI1PDZ6NkOy
NIH-3T3 MnXIT4lv[XOnIFHzd4F6 M3LHNFEhcA>? NHraZVhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1? MkH5NlQ5OTlzMU[=
NIH-3T3 MXfLbY5ie2ViQYPzZZk> NHK2N|EyKGh? M4e1NGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>? NG\vVY0zPDhzOUGxOi=>
NIH-3T3 MlPRT4lv[XOnIFHzd4F6 NXzJN2RPOSCq MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> NXTB[llIOjR6MUmxNVY>
NIH-3T3 NIjW[45McW6jc3WgRZN{[Xl? M{DidVEhcA>? MXrJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MWKyOFgyQTFzNh?=
KARPAS299 NVGzOpRiU2mwYYPlJGF{e2G7 M1:xVlkxKG2rbh?= NGPqRZJFVVOR NG\Tb4xKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGsheGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6xNUDPxE1? MXmyOFkxODd3MB?=
MKN 45 NELPO2ZMcW6jc3WgRZN{[Xl? M{C3b|EhcA>? M1i4OmROW09? MkLSTY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO Ml;XNlQ6ODB5NUC=
A549 MYLDfZRwfG:6aXOgRZN{[Xl? NE\Xe|k1QCCq M3;hUWROW09? M3PiV2lEPTBib3[gOE4xQDRizszN MUOyOFkxODh|MB?=
NCI-H1975 NIPmS2hEgXSxdH;4bYMhSXO|YYm= MnnWOFghcA>? NWTYNWtVTE2VTx?= M4PabGlEPTBib3[gO{42PTFizszN MWKyOFkxODh|MB?=
NCI-H1993 Mn;QR5l1d3SxeHnjJGF{e2G7 M1TWSFQ5KGh? M1O1RmROW09? NH;qNXhKSzVyIH;mJFAvODZzIN88US=> MkLENlQ6ODB6M{C=
NCI-H1993 Ml3XRZBwfG:|aYOgRZN{[Xl? NH3XN4UyKM7:TR?= NFjIXWgzPCCq NWTTOXlpTE2VTx?= NYjkdWNE\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> M3Pz[VI1QTByOEOw
NIH-3T3 Ml;SR5l1d3SxeHnjJGF{e2G7 M1vmRlQ5KGh? MmDISG1UVw>? NGDQWGNKSzVyIH;mJFAvOzZ2IN88US=> NInLR4gzPDlyMEizNC=>
EBC1 M1TQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG3NkBp M{fNNGROW09? NWDpNFNXUUN3MDDv[kAxNjByNkmg{txO M1PjelI1QTByOEOx
KARPAS299 M2nKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3NkBp NW\QVHB{TE2VTx?= Mo\RTWM2OCCxZjCwMlIh|ryP NG\RWoozPDlyMEizNS=>
NB1 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXh[HlKSzVyPUmxMlk5KG6P MorFV2FPT0WU
NCI-SNU-5 NU\He4hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4XGRKSzVyPUGwOU44PSCwTR?= MnLoV2FPT0WU
SR NGrBd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF{Nj6zNUBvVQ>? MnvtV2FPT0WU
SF539 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HBNmlEPTB;MkC0MlI1KG6P MWDTRW5ITVJ?
SU-DHL-1 NVjMSmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXpPHExUUN3ME2zN|YvQDJibl2= MUPTRW5ITVJ?
SCC-3 M2PNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrnPIpKSzVyPUO1Ok44PiCwTR?= M4HHWHNCVkeHUh?=
DEL MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN4OT65JI5O NG\nOFdUSU6JRWK=
CTV-1 NYj5Z4hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LqfmlEPTB;NUm2MlQ5KG6P MVnTRW5ITVJ?
EM-2 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SyPGlEPTB;NkCxMlM1KG6P MVLTRW5ITVJ?
MHH-CALL-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILtVFlKSzVyPU[4Nk42PyCwTR?= M{DmUHNCVkeHUh?=
KM12 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2frZmlEPTB;N{C2Mlkhdk1? MXrTRW5ITVJ?
KINGS-1 NYro[IF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC3PJBKSzVyPUe0PU44PSCwTR?= NH;1bnZUSU6JRWK=
MEG-01 M1fmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDMSYFKSzVyPUi1O{43PiCwTR?= NWrKZnlLW0GQR1XS
BV-173 NHvCPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq2OVNKSzVyPUGuNFU6QTdizszN M1PNeHNCVkeHUh?=
LAMA-84 NIjHZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XSeGlEPTB;MT6zPFI5OiEQvF2= NEn0SG5USU6JRWK=
KARPAS-299 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfHXIs{UUN3ME2xMlQxQDZzIN88US=> MkfRV2FPT0WU
K-562 NFvyeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrRTWM2OD1zLkeyNlY6KM7:TR?= M{LyPXNCVkeHUh?=
SK-LMS-1 NWj2OodnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrGNnBKSzVyPUGuO|Y5PjdizszN MkHnV2FPT0WU
MOLT-16 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwOUW1O|Uh|ryP NUTpdlRHW0GQR1XS
CMK NEC0ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTSlZKSzVyPUGuPVYyPTlizszN M{TpNXNCVkeHUh?=
ST486 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvDdGJ2UUN3ME2yMlQ{ODd|IN88US=> NUTPSWJEW0GQR1XS
CI-1 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf0eo1KUUN3ME2yMlQ6PjV7IN88US=> MXzTRW5ITVJ?
KP-N-RT-BM-1 NVPmZWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfjVHJKSzVyPUKuO|AyOjJizszN NGHibW5USU6JRWK=
ALL-PO MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TyeWlEPTB;Mz6xPFIxPyEQvF2= NULrdINKW0GQR1XS
KS-1 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwMkGyNlUh|ryP NUP0bYpYW0GQR1XS
Becker MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnETWM2OD12LkKzPVMh|ryP M2fCV3NCVkeHUh?=
GDM-1 NHnpRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jISWlEPTB;ND6yOFYyPyEQvF2= NIW5V2pUSU6JRWK=
BC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGruZnJKSzVyPUSuOFkzPzdizszN NXziXJNMW0GQR1XS
NB14 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TSTWlEPTB;ND64N|UzPCEQvF2= M{TXOXNCVkeHUh?=
NOS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLLbIVKSzVyPUWuN|M5PzRizszN M2DZXHNCVkeHUh?=
MZ1-PC NGHFbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTVwOEKxOVEh|ryP NFLvUmdUSU6JRWK=
A498 NV\DbnBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfve4t3UUN3ME22MlA5PDd|IN88US=> NWD5W25TW0GQR1XS
EW-16 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPmTWM2OD14LkO3O|c{KM7:TR?= M1jxTXNCVkeHUh?=
NALM-6 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fEZ2lEPTB;Nj62PFM5PyEQvF2= NV3vfFhyW0GQR1XS
EB-3 NH7CenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLQTWM2OD15LkC3NlM{KM7:TR?= MXjTRW5ITVJ?
697 NXLid2lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS4TWM2OD17LkK0N|I6KM7:TR?= NEfGcpBUSU6JRWK=
Ramos-2G6-4C10 NXTVe2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTlwNUm4OFIh|ryP MnfyV2FPT0WU
KNS-81-FD M4TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTsO2VOUUN3ME25MlY6PjV|IN88US=> MoL0V2FPT0WU
HUTU-80 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y4V2lEPTB;OT63OFY1OiEQvF2= NVTKbIM{W0GQR1XS
LS-411N NVPrXXR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFyLkC1Olch|ryP MoDTV2FPT0WU
RPMI-8402 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFyLkGxOkDPxE1? NFn1RppUSU6JRWK=
KU812 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjwbGZqUUN3ME2xNE4zQTlzIN88US=> M3fBV3NCVkeHUh?=
EW-1 NX7rb4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjaUYpKSzVyPUGwMlQ1OjVizszN MVvTRW5ITVJ?
HC-1 NISyeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WydmlEPTB;MUCuOFg1PCEQvF2= MVfTRW5ITVJ?
NB69 NUXXNXNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELqSnNKSzVyPUGwMlUxPDNizszN MoLqV2FPT0WU
MFH-ino MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zvZmlEPTB;MUCuPFMxOyEQvF2= MofIV2FPT0WU
CCRF-CEM Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFricVVKSzVyPUGxMlU6PyEQvF2= NWC3R3BKW0GQR1XS
SK-N-DZ NWTUbG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtT49KSzVyPUGyMlA1OzZizszN NHLC[pJUSU6JRWK=
NCI-H720 NH3ucGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPvOphKSzVyPUGyMlE4ODVizszN M1i4XXNCVkeHUh?=
HCC1187 M2LV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrKRmx7UUN3ME2xNk4zODRzIN88US=> MYjTRW5ITVJ?
IST-SL2 M3fFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPJTWM2OD1zMj60PFczKM7:TR?= MkK0V2FPT0WU
KE-37 NEfsSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfoVIZKSzVyPUGyMlc6PjZizszN Mli5V2FPT0WU
HCC1599 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\VTWM2OD1zMj65NFY6KM7:TR?= MVTTRW5ITVJ?
A4-Fuk NFjLd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknXTWM2OD1zMj65OVg3KM7:TR?= MnnWV2FPT0WU
NKM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnyTWM2OD1zMz6yPVI2KM7:TR?= MXrTRW5ITVJ?
BE-13 NHPBPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnZTWM2OD1zMz63PVg6KM7:TR?= MkPFV2FPT0WU
MV-4-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD1zND6wN|I1KM7:TR?= MnL5V2FPT0WU
OPM-2 M17uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3mTWM2OD1zND60NFg2KM7:TR?= MmLDV2FPT0WU
KARPAS-422 NX3tcHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XpdmlEPTB;MUSuOVEzPiEQvF2= NVLs[XVzW0GQR1XS
RPMI-8226 NIHLdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF2Lki5NVUh|ryP M13IbnNCVkeHUh?=
KARPAS-45 M4LtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3Lke3NVYh|ryP NVPleW1UW0GQR1XS
SK-PN-DW MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOxcZdLUUN3ME2xOU45PjNzIN88US=> MYLTRW5ITVJ?
LC-2 M2O2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF4LkG1NFYh|ryP NILreYVUSU6JRWK=
NCI-H1648 NUnIS2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[xRZFtUUN3ME2xOk4zPTRizszN NGjnN5hUSU6JRWK=
RL95-2 NYOx[G8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULUPW93UUN3ME2xOk4{QTd6IN88US=> MVnTRW5ITVJ?
KNS-42 M1ziVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF4LkeyO|Qh|ryP MX7TRW5ITVJ?
RPMI-6666 NXz6botpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LRb2lEPTB;MU[uPVIyOSEQvF2= Mnq0V2FPT0WU
SIG-M5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwe5lKSzVyPUG3MlE6ODNizszN Mo\jV2FPT0WU
VA-ES-BJ Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljkTWM2OD1zNz63OFUyKM7:TR?= NUewcmNSW0GQR1XS
MONO-MAC-6 NWPqfXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF5LkmzNVIh|ryP NXLMV5R3W0GQR1XS
LAN-6 NFH4OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTRZlKSzVyPUG4Mlc2PTdizszN NFm4U4xUSU6JRWK=
A388 M1rZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFT2lKSzVyPUG5MlMxPTlizszN NYXoTIRlW0GQR1XS
SK-NEP-1 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJyLkKxN|Ih|ryP M2i0fXNCVkeHUh?=
TE-10 NYLFdWdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\jOJdKSzVyPUKwMlUzOjFizszN NV\EXHhwW0GQR1XS
HL-60 M4q3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyTmpKSzVyPUKwMlkxQTlizszN M4XnN3NCVkeHUh?=
MC116 NF;oTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K5UmlEPTB;MkGuO|IzOSEQvF2= NHPWfWNUSU6JRWK=
SW962 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvFTWM2OD1{MT63PVE2KM7:TR?= M4TUZ3NCVkeHUh?=
NOMO-1 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XmSGlEPTB;MkKuOlU3PCEQvF2= Ml;TV2FPT0WU
CTB-1 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ{Lki2O|Eh|ryP M{W4OnNCVkeHUh?=
MRK-nu-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnqXZpsUUN3ME2yNk46ODd2IN88US=> M3m1XHNCVkeHUh?=
GR-ST MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ|Lke2JO69VQ>? MkDsV2FPT0WU
HH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\PTWM2OD1{ND6wNFMh|ryP Ml7EV2FPT0WU
NCI-H1963 NG\TUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PlNmlEPTB;MkSuNFc5OiEQvF2= Mn;SV2FPT0WU
QIMR-WIL M2rwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi4bIFKSzVyPUK0Mlg4PzJizszN MVXTRW5ITVJ?
CGTH-W-1 NYGy[FFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYe5WpltUUN3ME2yOU4xPzJ|IN88US=> Ml3WV2FPT0WU
LP-1 NYq0b5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOxTWM2OD1{NT62OVUyKM7:TR?= MV7TRW5ITVJ?
NCI-H748 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ4LkWxN|ch|ryP NFLpVG1USU6JRWK=
PF-382 NXzseZJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnZeINvUUN3ME2yO{4zOjJ|IN88US=> NWrCbJNwW0GQR1XS
ATN-1 NIHtPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LKN2lEPTB;MkeuN|c{OiEQvF2= Mn\pV2FPT0WU
L-540 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD1{Nz62OFU6KM7:TR?= MkX2V2FPT0WU
LXF-289 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ5Lke1NVkh|ryP MkKwV2FPT0WU
LS-513 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvc2lEPTB;MkiuNVgxPyEQvF2= Mn3nV2FPT0WU
NCI-H1581 M3jXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrUV|JRUUN3ME2zNE4{QTd4IN88US=> NIjZTXBUSU6JRWK=
ES6 M{DLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoixTWM2OD1|MD62PFk6KM7:TR?= MmHiV2FPT0WU
SW982 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTDdVdKSzVyPUOwMlg2PjZizszN M3rGW3NCVkeHUh?=
DOHH-2 NXv0TIdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvHTWM2OD1|MT61PFk{KM7:TR?= NYj0TZRYW0GQR1XS
DB MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN|Lkm0N|Eh|ryP MonaV2FPT0WU
MPP-89 NWjTbXROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\vZWlEPTB;M{SuNVc2PiEQvF2= MkCzV2FPT0WU
LB831-BLC M3H6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN2LkWxPFQh|ryP NETqUFdUSU6JRWK=
NB5 NWfwOG9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXLeYJ[UUN3ME2zOE45PTN3IN88US=> M{PBbXNCVkeHUh?=
GB-1 NVTJO5d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTN3LkC0Olkh|ryP NVfodmNMW0GQR1XS
TE-15 NILZU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lt[mlEPTB;M{WuNlI{QCEQvF2= NXfWOXY5W0GQR1XS
LC4-1 NWDlZZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDCV5NKSzVyPUO1MlM5PDdizszN NWnJb2U5W0GQR1XS
NCI-H747 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPITIpoUUN3ME2zOk4yOzZ7IN88US=> NXP6VJJ3W0GQR1XS
NTERA-S-cl-D1 NHvMOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN6LkezOFch|ryP MnP6V2FPT0WU
SK-MM-2 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KybmlEPTB;NECuNVE1PiEQvF2= MUDTRW5ITVJ?
TGW M1e2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRzLkC1OlMh|ryP NHjrNGRUSU6JRWK=
ONS-76 NFu0UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWyRndDUUN3ME20Nk41QDh|IN88US=> NXXDclhkW0GQR1XS
CPC-N NWru[5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu0TWM2OD12Mj65PVcyKM7:TR?= NXHXXY9PW0GQR1XS
ES4 NFPuSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hu[GlEPTB;NESuOFE2OyEQvF2= NFjvPFlUSU6JRWK=
Daudi M131WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCOGlEPTB;NEWuNFgzPyEQvF2= NH6x[ZhUSU6JRWK=
MOLT-4 NF\vbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD12NT6wPFU{KM7:TR?= NYjGWGYxW0GQR1XS
HT-144 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDvUldKSzVyPUS2MlczPiEQvF2= MmXJV2FPT0WU
SW872 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHjTWM2OD12OD6xPVM{KM7:TR?= NEDyU4NUSU6JRWK=
D-283MED MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXSfoJKSzVyPUS4MlM2PDJizszN NY\sfpBWW0GQR1XS
NCI-H2126 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR6Lki0O|Yh|ryP MXTTRW5ITVJ?
NCI-SNU-16 NVfBSmlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TmOmlEPTB;NEmuNlE1OyEQvF2= M1e2XnNCVkeHUh?=
CESS NV3wNWljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzjTWM2OD12OT61NFg5KM7:TR?= NXyxdHZWW0GQR1XS
A101D Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR7Lkm3N|Yh|ryP MVPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
In vivo

In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

- Collapse

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

- Collapse
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03439215 Recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l. June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Recruiting Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2
NCT02499614 Unknown status Drug: Crizotinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale December 2014 Phase 2
NCT02510001 Active not recruiting Drug: PF-02341066|Drug: PD-0325901|Drug: Binimetinib Solid Tumor|Colorectal Cancer University of Oxford|Queen''s University Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital Antwerp|Hospital Vall d''Hebron|Saint Antoine University Hospital|European Georges Pompidou Hospital|Pfizer|University of Turin Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|University of Paris 5 - Rene Descartes November 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID